1. Volume 136, Issue 1, Pages 94-100 (July 2015)
Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands 
Yumao Zhang, Anthonius de Boer, Talitha I. Verhoef, Felix J.M. van der Meer, Saskia Le Cessie, Anke H. Maitland-van der Zee Rita Barallon, Anthonius de Boer, Ann Daly, Anke-Hilse Maitland-van der Zee, Ken Redekop, Julia Stingl, Vangelis G. Manolopoulos, Frits R. Rosendaal, Mia Wadelius Yumao Zhang, Anthonius de Boer, Talitha I. Verhoef, Felix J.M. van der Meer, Saskia Le Cessie, Anke H. Maitland-van der Zee Rita Barallon, Anthonius de Boer, Ann Daly, Anke-Hilse Maitland-van der Zee, Ken Redekop, Julia Stingl, Vangelis G. Manolopoulos, Frits R. Rosendaal, Mia Wadelius 
Thrombosis Research 
Volume 136, Issue 1, Pages (July 2015)
DOI: /j.thromres
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Fig. 1
Percentage of time with INR below 2 in different time periods; A: acenocoumarol (ACE); B: phenprocoumon (PHE). All the data are indicated as mean±95% confidence interval (⁎⁎P<0.01; ⁎P<0.05).
Thrombosis Research  , DOI: ( /j.thromres )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Fig. 2
Percentage of time with INR above 3.5 in different time periods; A: acenocoumarol (ACE); B: phenprocoumon (PHE). All the data are indicated as mean±95% confidence interval (⁎⁎P<0.01; ⁎P<0.05).
Thrombosis Research  , DOI: ( /j.thromres )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Fig. 3
Percentage of time in INR range during 12weeks and the first 4weeks for standard care, clinical dosing and pharmacogenetic-guided dosing. A:acenocoumarol. B:phenprocoumon. Data of the genotype-guided group was from the Table 2 of the EU-PACT trial [1].
Thrombosis Research  , DOI: ( /j.thromres )
Copyright © 2015 Elsevier Ltd Terms and Conditions